Common Causes of Mortality in Dialysis Patients

Cardiovascular disease is the leading cause of death in the dialysis population, with mortality rates 10-20 times higher than the general population. Hyperkalaemia, often resulting from missed dialysis or dietary indiscretion, is the most common cause of sudden death in end-stage renal disease patients. Hypocalcaemia is a common manifestation of CKD and should be treated with calcium supplements. While there is no known association between reduced renal function and overall cancer risk, some studies suggest an increased risk of urinary, endocrine, and digestive tract cancers among dialysis patients. Sepsis related to dialysis is rare with modern techniques, but minimizing the use of temporary catheters can further reduce the risk.

Lhermitte’s sign is a well-known symptom that suggests the presence of an underlying condition in the cervical cord’s dorsal column nuclei. This sign is also observed in cases of subacute combined degeneration of the cord and cervical stenosis.

Multiple Sclerosis: Common Features and Diagnostic Criteria

Multiple sclerosis (MS) is a disease that can present with various non-specific features, such as significant lethargy in around 75% of patients. Diagnosis of MS can be made based on two or more relapses and either objective clinical evidence of two or more lesions or objective clinical evidence of one lesion together with reasonable historical evidence of a previous relapse.

MS can affect different parts of the body, leading to a range of symptoms. Visual symptoms are common, with optic neuritis being a frequent presenting feature. Other visual symptoms include optic atrophy, Uhthoff’s phenomenon (worsening of vision following a rise in body temperature), and internuclear ophthalmoplegia. Sensory symptoms may include pins and needles, numbness, trigeminal neuralgia, and Lhermitte’s syndrome (paraesthesiae in limbs on neck flexion). Motor symptoms may include spastic weakness, which is most commonly seen in the legs. Cerebellar symptoms such as ataxia and tremor may also occur.

In addition to these symptoms, MS can also cause urinary incontinence, sexual dysfunction, and intellectual deterioration. It is important to note that not all patients with MS will experience all of these symptoms, and the severity and frequency of symptoms can vary widely between individuals.

According to NICE 2017 guidelines, if a patient with asthma is not effectively managed with a SABA + ICS, the first step should be to add a LTRA rather than a LABA.

The management of asthma in adults has been updated by NICE in 2017, following the 2016 BTS guidelines. One of the significant changes is in ‘step 3’, where patients on a SABA + ICS whose asthma is not well controlled should be offered a leukotriene receptor antagonist instead of a LABA. NICE does not follow the stepwise approach of the previous BTS guidelines, but to make the guidelines easier to follow, we have added our own steps. The steps range from newly-diagnosed asthma to SABA +/- LTRA + one of the following options, including increasing ICS to high-dose, a trial of an additional drug, or seeking advice from a healthcare professional with expertise in asthma. Maintenance and reliever therapy (MART) is a form of combined ICS and LABA treatment that is only available for ICS and LABA combinations in which the LABA has a fast-acting component. It should be noted that NICE does not recommend changing treatment in patients who have well-controlled asthma simply to adhere to the latest guidance. The definitions of what constitutes a low, moderate, or high-dose ICS have also changed, with <= 400 micrograms budesonide or equivalent being a low dose, 400 micrograms - 800 micrograms budesonide or equivalent being a moderate dose, and > 800 micrograms budesonide or equivalent being a high dose for adults.

The symptoms exhibited by this individual suggest the presence of secondary syphilis.

Understanding Syphilis: Symptoms and Stages

Syphilis is a sexually transmitted infection caused by the bacterium Treponema pallidum. The infection progresses through three stages: primary, secondary, and tertiary. The incubation period can range from 9 to 90 days.

During the primary stage, a painless ulcer called a chancre appears at the site of sexual contact. Local lymph nodes may also become swollen, but this symptom may not be visible in women if the lesion is on the cervix.

The secondary stage occurs 6 to 10 weeks after the primary infection and is characterized by systemic symptoms such as fevers and lymphadenopathy. A rash may appear on the trunk, palms, and soles, along with buccal ulcers and painless warty lesions on the genitalia.

In the tertiary stage, granulomatous lesions called gummas may develop on the skin and bones, and there may be an ascending aortic aneurysm. Other symptoms include general paralysis of the insane, tabes dorsalis, and Argyll-Robertson pupil.

Congenital syphilis can also occur if a pregnant woman is infected. Symptoms include blunted upper incisor teeth, linear scars at the angle of the mouth, keratitis, saber shins, saddle nose, and deafness.

Understanding the symptoms and stages of syphilis is important for early detection and treatment. It is a treatable infection, but if left untreated, it can lead to serious complications.

Neonatal respiratory distress syndrome (NRDS) is a condition that primarily affects premature newborns due to a lack of surfactant. This deficiency causes an increase in alveolar surface tension, leading to reduced compliance and increased breathing effort. The production of surfactant in the fetus is aided by natural maternal glucocorticosteroids, and synthetic steroids are the first-line treatment for preventing NRDS in high-risk pregnancies. Tocolytics, which can delay preterm labor, are not typically used, but may be considered in certain cases to allow time for maternal steroids to take effect. While curosurf, continuous positive airway pressure, and extracorporeal membrane oxygenation can be effective treatments for NRDS, they are not used as preventative measures.

Surfactant Deficient Lung Disease in Premature Infants

Surfactant deficient lung disease (SDLD), previously known as hyaline membrane disease, is a condition that affects premature infants. It occurs due to the underproduction of surfactant and the immaturity of the lungs’ structure. The risk of SDLD decreases with gestation, with 50% of infants born at 26-28 weeks and 25% of infants born at 30-31 weeks being affected. Other risk factors include male sex, diabetic mothers, Caesarean section, and being the second born of premature twins.

The clinical features of SDLD are similar to those of respiratory distress in newborns, including tachypnea, intercostal recession, expiratory grunting, and cyanosis. Chest x-rays typically show a ground-glass appearance with an indistinct heart border.

Prevention during pregnancy involves administering maternal corticosteroids to induce fetal lung maturation. Management of SDLD includes oxygen therapy, assisted ventilation, and exogenous surfactant given via an endotracheal tube. With proper management, the prognosis for infants with SDLD is generally good.

Understanding Immune Thrombocytopenia (ITP) in Adults

Immune thrombocytopenia (ITP) is a condition where the immune system attacks and reduces the number of platelets in the blood. This is caused by antibodies targeting the glycoprotein IIb/IIIa or Ib-V-IX complex. While children with ITP usually experience acute thrombocytopenia after an infection or vaccination, adults tend to have a more chronic form of the condition. ITP is more common in older females and may be detected incidentally during routine blood tests. Symptoms may include petechiae, purpura, and bleeding, but catastrophic bleeding is not a common presentation.

To diagnose ITP, a full blood count and blood film are typically performed. While a bone marrow examination is no longer routinely used, antiplatelet antibody testing may be done, although it has poor sensitivity and does not affect clinical management. The first-line treatment for ITP is oral prednisolone, but pooled normal human immunoglobulin (IVIG) may also be used if active bleeding or an urgent invasive procedure is required. Splenectomy is now less commonly used as a treatment option.

In some cases, ITP may be associated with autoimmune haemolytic anaemia (AIHA), which is known as Evan’s syndrome. It is important for individuals with ITP to work closely with their healthcare provider to manage their condition and prevent complications.

To diagnose gestational diabetes, a fasting glucose level of >= 5.6 mmol/L or a 2-hour glucose level of >= 7.8 mmol/L can be used. A patient with a BMI of >30 kg/m² and symptoms of polydipsia and polyuria should undergo an oral glucose tolerance test during 24-28 weeks of pregnancy. In this test, the patient fasts for 8-10 hours, then drinks a glucose solution and has blood samples taken before and 2 hours after. A fasting glucose level of 5.9mmol/L or higher confirms the diagnosis of gestational diabetes.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

Understanding Cellulitis: Symptoms, Diagnosis, and Treatment

Cellulitis is a condition characterized by inflammation of the skin and subcutaneous tissues caused by bacterial infection, usually Streptococcus pyogenes or Staphylcoccus aureus. It commonly occurs on the shins and is accompanied by symptoms such as erythema, pain, and swelling. In some cases, patients may also experience systemic upset, including fever.

The diagnosis of cellulitis is typically made based on clinical presentation, and no further investigations are required in primary care. However, blood tests and cultures may be requested if the patient is admitted to the hospital and sepsis is suspected.

To guide the management of patients with cellulitis, healthcare providers may use the Eron classification system. Patients with Eron Class III or IV cellulitis, severe or rapidly deteriorating cellulitis, or certain risk factors such as immunocompromisation or significant lymphoedema should be admitted for intravenous antibiotics. Patients with Eron Class II cellulitis may not require admission if appropriate facilities and expertise are available in the community to administer intravenous antibiotics and monitor the patient.

The first-line treatment for mild to moderate cellulitis is flucloxacillin, while clarithromycin, erythromycin (in pregnancy), or doxycycline may be used in patients allergic to penicillin. Patients with severe cellulitis should be offered co-amoxiclav, cefuroxime, clindamycin, or ceftriaxone.

Overall, understanding the symptoms, diagnosis, and treatment of cellulitis is crucial for effective management of this common bacterial infection.

Heart failure is a complete contraindication for the use of pioglitazone and other thiazolidinediones.

Thiazolidinediones: A Class of Diabetes Medications

Thiazolidinediones are a type of medication used to treat type 2 diabetes. They work by activating the PPAR-gamma receptor, which reduces insulin resistance in the body. However, one medication in this class, rosiglitazone, was withdrawn in 2010 due to concerns about its cardiovascular side effects.

The PPAR-gamma receptor is a nuclear receptor found inside cells. It is naturally activated by free fatty acids and is involved in regulating the differentiation and function of adipocytes (fat cells).

While thiazolidinediones can be effective in treating diabetes, they can also have adverse effects. Patients may experience weight gain, liver impairment (which requires monitoring of liver function tests), and fluid retention. Thiazolidinediones are contraindicated in patients with heart failure due to the increased risk of fluid retention, especially if the patient is also taking insulin. Recent studies have also shown an increased risk of fractures and bladder cancer in patients taking pioglitazone, another medication in this class.

Investigations for Acute Interstitial Nephritis

Acute interstitial nephritis (AIN) can present with non-specific symptoms of acute kidney dysfunction, such as nausea, vomiting, and malaise. A decline in kidney function is typical, and a raised creatinine on U+ESs may already be present. A drug history, along with a raised eosinophilia on full blood count (FBC), can aid in the diagnosis of AIN. Common causes of AIN include drugs like proton-pump inhibitors, non-steroidal anti-inflammatories, and antibiotics, as well as autoimmune disorders or other systemic diseases.

Antinuclear antibody (ANA) testing should be performed to rule out systemic lupus erythematosus (SLE), which can coexist with AIN. However, a positive ANA test alone would not confirm a diagnosis of AIN.

Urinary dipstick testing for protein is not useful in diagnosing AIN, as patients with AIN typically do not have protein in their urine. Nephrotic syndrome can occur as a rare complication of AIN.

Renal biopsy may be necessary to confirm the diagnosis of AIN, as it is characterized by an inflammatory infiltrate in the kidney interstitium. However, if the patient’s condition is drug-induced, a renal biopsy may not be required if a raised creatinine and eosinophil count, along with the drug history, are sufficient for diagnosis.

Chest X-ray (CXR) may be necessary to investigate other potential causes of AIN, such as sarcoidosis. If sarcoidosis is suspected and the CXR is inconclusive, a computed tomography chest may be performed. However, if the patient has been exposed to a drug that predisposes them to AIN, a diagnosis of drug-induced interstitial nephritis is more likely than an underlying systemic disease.